anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adult patients with severe chronic kidney disease (CKD) are immunocompromised and known to have an increased risk of pneumococcal infection. To prevent the infection, immunization with pneumococcal polysaccharide vaccine (PPV23) is currently recommended in Canada; however, the vaccine effect in these patients is suboptimal because of their immune dysfunction. The second-generation pneumococcal vaccines (polysaccharide-protein conjugate) have superior immunogenicity in some immunocompromised adult individuals. In Canada, Prevnar 13 has recently been recommended by the NACI for certain categories of immunocompromised adults, such as HSCT recipients and HIV-positive patients. However, the NACI has concluded that there is currently insufficient evidence to recommend the use of Prevnar 13 in patients with chronic kidney disease. No published data on the use of pneumococcal conjugate vaccines in adults with CKD are available. Moreover, it is unknown whether a previous immunization with PPV23 may have a negative effect on the immune response to Prevnar 13 in these patients. Such a possibility exists due to the memory B-cells' depletion following immunization with pure polysaccharide antigens. In this case, additional doses of Prevnar 13 may be required to achieve the optimal protection. The conjugate vaccine will then expand the B-cell pool available to respond to subsequent antigen challenge. To test whether previous immunization with PPV23 affects the immune response of severe CKD patients to Prevnar 13, we will immunize two groups of adult stage 4 and 5 CKD patients attending the Thunder Bay Regional Health Sciences Centre with one dose of Prevnar 13 and will assess their initial immunological response, its longevity, and vaccine safety. The first group will consist of patients who had been immunized with PPV23 more than one year prior to the enrollment in this study and the second group will include patients without history of pneumococcal vaccination. Fold increase in antibody levels and OPA, as well as longevity of the immune response over a one-year period will be assessed as the surrogate for protection against pneumococcal infection. The immune response will be analyzed in the context of demographic and clinical characteristics of the vaccinated patients. All infectious episodes in the study participants will be recorded throughout one year of observation. We will also record all vaccine adverse effects following immunization and compare their frequency and severity between the two groups. The anticipated results of this trial will provide essential evidence to justify the use of Prevnar 13 for immunization of adult CKD patients.
Anxiety, pain and discomfort are situations of great stress in the daily routine of clinical practice, and especially in the practice of the dental emergency sector. Several studies have concluded that low-intensity laser therapy has been shown to be effective in pain management. However, the majority report the use of laser in the treatment of chronic pain, few studies show its application in acute pain and only one study evaluated the effect of low laser on acute pain of pulp inflammation, but with other parameters. In addition, because of the inflammatory process and several factors of unknown origin, the anesthetic agent can not always promote complete analgesia, especially when faced with mandibular molars. Therefore, the present study has the objective of evaluating whether the previous therapy with low intensity laser, through its analgesic effect, can promote a greater comfort specifically for this type of patient. 75 patients with pain from mandibular molar pulpitis will be selected for this study (randomized and double blind) and divided into 3 groups (n = 25): Group 1 - Pulse Laser (880nm, 30mW, 3,6J / cm², 25Hz) ; Group 2 - Continuous Laser (880nm; 30mW; 3.6J / cm²); Group 3 - Placebo. The pain will be evaluated by means of an VAS score in 6 different times: initial pain, immediately after and 10 minutes after irradiation with the laser, 10 minutes after inferior alveolar nerve block (IANB), during conventional endodontic treatment, after the end of the procedure. (T0, T1, T1 ', T2, T3 and T4). The efficacy of the laser application will be assessed using the VAS scale 10 minutes after the laser application, immediately before the blockade is performed. The use of the laser will be considered effective if the patient reports a reduction in the VAS scale of 2 points, between the initial moment and 10 minutes after the laser application. Analgesia will be evaluated during the pulpectomy procedure with the use of the verbal analogue scale 0 to 3. Analgesic effect will be considered if the professional can finish the procedure without the patient reporting 2 or 3 on this scale. The data obtained between the different groups and schedules will be compared statistically, and the statistical test chosen will depend on the normality of the data. The data obtained between the different groups and times will be compared statistically, and the statistical test chosen will depend on the normality of the data.
PURPOSE: A composite formulation containing saw palmetto and zinc sulfate is provided to treat prostate diseases, to improve normal immune function, to promote cell division, and to enhance stamina. CONSTITUTION: A method for preparing a composite formulation containing saw palmetto and zinc sulfate comprises the steps of: mixing 100 wt% of a saw palmetto fruit extract, 8-12 wt% of tocopherol, 10-14 wt% of sunflower seed oil, 2-6 wt% of soybean oil, and 28-32 wt% of palm oil to prepare a first mixture solution (102); adding a first emulsifier and a first surfactant to the first mixture solution and preparing an oil emulsified liquid (104); mixing an extract of Lycium fruit (10-14 wt%), Torilis japonica (Houtt.) DC. (2-6 wt%), Schisandra chinensis (Turcz.) Baill. (2-6 wt%), Cuscutae semen (4-8 wt%), and Rubus coreanus fruit (2-6 wt%), 10-14 wt% of a ginseng concentrate liquid, 2-6 wt% of a Scutellariae Radix concentrate liquid, and 10-14 wt% of zinc sulfate to prepare a second mixture solution (106); adding a second surfactant and a second emulsifier to the second mixture solution to prepare an aqueous emulsified liquid (108); mixing the oil emulsified liquid and the aqueous emulsified liquid to prepare a mixed emulsified liquid (110); and filling a soft capsule with the mixed emulsified liquid (112). [Reference numerals] (102) Mix a saw palmetto fruit extract, tocopherol, sunflower seed oil, soybean oil, and palm oil to prepare a first mixture solution; (104) Add sorbitan monooleate and glycein fatty acid to the first mixture solution and prepare an oil emulsified liquid; (106) React and stir mixing an extract of Lycium fruit, Torilis japonica (Houtt.) DC., Schisandra chinensis (Turcz.) Baill., Cuscutae semen, and Rubus coreanus fruit, a ginseng concentrate liquid, a Scutellariae Radix concentrate liquid, and zinc sulfate to prepare a second mixture solution; (108) Add sorbitan monooleate and glycein fatty acid to the second mixture solution and prepare an aqueous emulsified liquid; (110) React and mix the oil emulsified liquid and the aqueous emulsified liquid to prepare a mixed emulsified liquid; (112) Filling a soft capsule with the mixed emulsified liquid and prepare a composite formulation; (AA) Start; (BB) End
Eptacog beta (activated), a recombinant human factor VIIa (rFVIIa), was approved by the US Food and Drug Administration (FDA) in 2020 (SEVENFACT®, LFB & HEMA Biologics) and the European Medicines Agency (EMA) in 2022 (CEVENFACTA®, LFB). In Europe, eptacog beta is indicated for the treatment of bleeds and the prevention of bleeds during surgery or invasive procedures in adults and adolescents (≥12 years old) with congenital haemophilia A or B with high-titre inhibitors (≥5 BU) or with low-titre inhibitors who are expected to have a high anamnestic response to factor VIII or factor IX, or to be refractory to increased dosing of these factors. The efficacy and safety of eptacog beta were evaluated in three Phase III clinical studies, PERSEPT 1, 2 and 3. For the EMA filing dossier, the analysis of data from PERSEPT 1 and 2 differed from the analysis used to support the filing in the US. In this review, we summarise current data regarding the mode of action, clinical efficacy and safety of eptacog beta for the management of haemophilia A and B in patients with inhibitors from a European perspective. In addition to providing a valuable summary of the analyses of the clinical data for eptacog beta conducted for the EMA, our review summarises the potential differentiators for eptacog beta compared with other current bypassing agents.
<P>PROBLEM TO BE SOLVED: To provide a treating method which disinfects and exterminates the ringworm fungi and miscellaneous germs by softening the keratin for the deeper permeation of the ringworm drug into the cuticle and the dermis.  <P>SOLUTION: To minimize the use of the ringworm drug, the inner sock should be put on the affected foot (omittable depending on the case) or a non-liquid spillage bag should be put on the affected bear foot, the opening thereof is tied and a cover sock or something for tightening the bag is put on and then, the bag is made better fit on the foot. The ringworm drug is placed into the bag beyond the range thereof determined allowed for the possible breeding of the ringworm fungi in the bag so that the foot is dipped thereinto per unit time until the drug permeates thoroughly into the keratin, cuticle and dermis to exterminate the ringworm fungi. The socks, the shoes, the bath room mats and the bathroom floors in which the ringworm fungi and the miscellaneous germs are breeding are sterilized and disinfected to prevent the repeated infection from occurring. The sterilization and disinfection are conducted once or so per week to prevent the infection of the ringwork fungi and miscellaneous germs after the complete healing.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Grave's disease is one of the most common autoimmune diseases. Thyroid eye disease is affecting nearly 50% of patients with Grave's disease. European guidelines recommend treating patients with serious TED in the acute face with intravenous steroids for 12 weeks. This treatment is burdened with metabolic complications, like raised blood pressure, high blood glucose, worsening of diabetes, osteoporosis, and weight gain. In addition, peptic ulcer and psychological disturbances are frequently seen. Long-term treatment with high doses of steroids could also suppress the corticotropic axis for a variable time period, giving temporary iatrogenic adrenal insufficiency. It is paramount to develop a treatment with equal or better effect and fewer complications for this group of patients. Recently, Teprotumumab, which act by inhibiting Insulin-Like Growth Factor-1 (IGF-1), has been introduced in treatment of TED. This represents a new area in the anti-inflammatory treatment of the disease. The anti-inflammatory effect of Sirolimus has not been examined in patients with TED, but there are two promising case-reports describing excellent response. Sirolimus have multiple immunosuppressive actions that may be favourable in the inflammatory response in TED. These are: inhibiting T-cell activation, anti-fibroblast effect and blocking the IGF-1 pathway. In contrast to other immunosuppressive drugs, Sirolimus is associated few side effects at low doses.

The investigators are planning a comparative study of conventional treatment (corticosteroids) compared with Sirolimus, regarding clinical outcomes and adverse effects. The investigators plan to include a total of 60 patients (30 in each group) with moderate to severe TED over a period of approximately 3 years.
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) surveillance is associated with improved early detection and reduced mortality, although practice patterns and effectiveness vary in clinical practice. We aimed to characterize HCC surveillance patterns in a large, diverse cohort of patients with HCC.
METHODS: We conducted a retrospective cohort study of patients diagnosed with HCC between January 2008 and December 2022 at 2 large US health systems. We recorded imaging receipt in the year before HCC diagnosis: ultrasound plus α-fetoprotein (AFP), ultrasound alone, multiphasic contrast-enhanced computed tomography (CT)/magnetic resonance imaging (MRI), and no liver imaging. We used multivariable logistic and Cox regression analysis to compare early tumor detection, curative treatment receipt, and overall survival between surveillance strategies.
RESULTS: Among 2028 patients with HCC (46.7% Barcelona Clinic Liver Cancer stage A), 703 (34.7%) had ultrasound plus AFP, 293 (14.5%) had ultrasound alone, 326 (16.1%) had multiphasic CT/MRI, and 706 (34.8%) had no imaging in the year before HCC diagnosis. Over the study period, proportions without imaging were stable, whereas use of CT/MRI increased. Compared with no imaging, CT/MRI and ultrasound plus AFP, but not ultrasound alone, were associated with early stage HCC detection and curative treatment. Compared with ultrasound alone, CT/MRI and ultrasound plus AFP were associated with increased early stage detection.
CONCLUSIONS: HCC surveillance patterns vary in clinical practice and are associated with differing clinical outcomes. While awaiting data to determine if CT or MRI surveillance can be performed in a cost-effective manner in selected patients, AFP has a complementary role to ultrasound-based surveillance, supporting its adoption in practice guidelines.
1,202,796. Compacted polyester powder. IMPERIAL CHEMICAL INDUSTRIES Ltd. 18 March, 1969 [1 April, 1966], No. 15541/68. Heading C3R. [Also in Division A5] The invention comprises a compacted aggregate of finely divided linear polyester particles. Specified polyesters are polyethylene iso-, ortho- and tere-phthalate and copolyesters or mixtures thereof. Specified particle size is 1-10 microns. The particles may be prepared by precipitation of the polyester from a solution in, for example, propylene carbonate and may be compacted using a plate press or a rotating platform type press. The particles may be perfume-laden for use as a cosmetic and may be mixed with, for example, talc, zinc stearate, starch, chalk, magnesium carbonate, kaolin, iron oxides, zinc and magnesium salts of fatty acids, titanium dioxide, zinc oxide or magnesium oxide.
BACKGROUND: To date, inconsistent evidence exists on the role of hypernatremia in patients with aneurysmal subarachnoid hemorrhage (aSAH) who underwent surgical clipping. We aimed to investigate the association between serum sodium and mortality in these patients.
METHODS: A cohort study was performed to include adult patients with aSAH who underwent surgical clipping in a university hospital. The primary outcome was follow-up mortality. Propensity score matching (PSM) was used for matching patients' baseline characteristics. Net reclassification improvement (NRI), and integrated discrimination improvement (IDI) were calculated to assess and compare the reclassification and discrimination capacity of different models. Trends in serum sodium over time were detected by the ordinary least squares model.
RESULTS: Of 618 aSAH patients with surgical clipping during the study period, normal serum sodium was observed in 467 patients (75.6 %), and admission hypernatremia was noted in 151 patients (24.4 %). After adjustment with multivariate regression analysis, patients with hypernatremia had significantly higher odds for follow-up mortality (aOR: 2.86, 95 % CI: 1.54 to 5.30; P = 0.001). PSM analysis observed similar results (aOR: 2.38, 95 % CI: 1.29 to 4.55; P = 0.009). The incorporation of serum sodium during hospitalization markedly enhanced the IDI (P < 0.001) and NRI (P < 0.001) for the prediction of mortality.
CONCLUSIONS: In conclusion, the findings from this cohort study of aSAH patients with surgical clipping indicated that serum sodium can be an independent predictive factor of all-cause mortality, and inferior sequelae in aSAH patients. These findings endorsed the importance of managing hypernatremia and monitoring serum sodium in patients with aSAH.
Urinary incontinence refers to the involuntary loss of urine in sufficient amounts to be considered a social or health problem. It is under-reported and under-treated as patients are often ashamed and embarrassed to discuss their condition and clinicians may also fail to ask patients about incontinence. This is a multi-center, open-label study including dose conversion and dose determination to evaluate the safety of OROS® oxybutynin chloride at a clinically acceptable dose. There are three study periods: Run-in, Dose Conversion/Determination, and Maintenance. During the 1-week Run-in Period, baseline incontinence, urinary frequency, and health related quality-of-life data are collected. During the Dose Conversion/Determination Period, any previous urge urinary incontinence medications are discontinued and each patient is started on OROS® oxybutynin chloride. The dose is titrated to a clinically acceptable dose in 5-mg increments at 7 ± 3 day intervals to a possible maximum dose of 30 mg/day. The clinically acceptable dose is defined as either the minimum effective dose (i.e., the dose at which the patient has no incontinent episodes for the last 2 days of the dosing interval) or the dose providing the best balance between symptomatic improvement and side effects. Patients taking immediate-release oxybutynin at enrollment started dose titration on OROS® oxybutynin chloride at a dose equal to their immediate-release oxybutynin dose; all others started at 5 mg per day OROS® (oxybutynin chloride). After the clinically acceptable dose is established, the patient continues for an additional week at that dose to confirm that it is appropriate. Then the patient enters the 12-week Maintenance Period that evaluates whether the urge urinary incontinence reduction that is achieved by the beginning of maintenance has persisted. The primary outcome of the study is an evaluation of the safety of OROS® oxybutynin chloride. Safety assessments include the incidence of adverse events, physical examination and medical history, clinical laboratory tests, urinalysis, electrocardiograms (ECGs), vital signs, and the Physician's Anticholinergic Effects Assessment (P-ACEA), an assessment completed by the physician if severe or intolerable anticholinergic effects occur.

OROS® oxybutynin chloride (5 mg and 10 mg systems): One to five systems taken orally per day (5 mg per day to a maximum of 30 mg per day) as a single morning dose. The duration of the Maintenance Period of the study is 12 weeks.
PURPOSE:To provide a hair dye composed of an acid dye and an oxidizing agent, used in an acidic region and effective in eliminating various troubles, e.g. skin irritation such as allergy, excessive hair damage, insufficient expression of color tone and narrow contrast width. CONSTITUTION:An acid dye is used in combination with an oxidizing agent in an acidic range of pH 2-7 and is properly compounded with a pH-modifier, a dyeing assistant, a thickener, etc. If necessary, the composition is further compounded with an oily component, a surfactant, a conditioning agent, a metal sequestering agent, an ultraviolet absorber, an antiseptic, a perfumery, etc., to obtain the objective dye. The acid dye is a water-soluble dye having an acidic group such as sulfone group or carboxyl group in the molecule and is compounded in a amount to give the total effective dye concentration of 0.1-8wt.% in dyeing. The oxidizing agent is powder (e.g. ammonium persulfate) or liquid (e.g. hydrogen peroxide) and is compounded in an amount of 1-40wt.%.
The present invention relates to a positive molecular bone reinforcing agent and preparation process thereof, which belongs to the field of food processing and preparation. Besides calcium and magnesium, the bone reinforcing agent also comprises trace elements containing copper, iron, zinc, manganese, iodine, etc. and vitamins containing vitamin C, vitamin D, vitamin B6, folic acid, etc., and metallic elements containing the calcium, the magnesium, etc. exist in the form of positive molecular carboxylate. The preparation process mainly comprises steps of raw material mixing, the flow addition of positive molecular carboxylic acid, vitamin addition, cooling, drying, pulverization, etc. The present invention has the advantages of equilibrium nutrient components, no toxicity, safety, reliability, easily obtained raw materials and simple production and has obvious effects for firming teeth and strengthening bone, fracture healing can be effectively promoted, and tooth and bone quality is roundly improved.
The invention discloses medical liquor for treating adult prickly heat. The medical liquor is prepared from the following raw materials by weight: 8-10g of astragalus membranaceus, 10-15g of honey-fried licorice roots, 3-4g of fructus cnidii, 2-4g of pillis ophidiae, 5-8g of fructus kochiae, 3-5g of rhizoma atractylodis, 2-4g of radix paeoniae alba, 5-8g of divaricate saposhnikovia roots, 1-3g of processed rhizoma pinelliae, 2-4g of fructus forsythia, 5-6g of pollen pini, 2-4g of oldenlandia diffusa, 1-3g of corydalis tubers, 2-4g of ulmus parvifolia stems and leaves, 1-3g of pale bittersweet leaves, 2-4g of dicranopteris roots, 8-10ml of gentamicin, 30-35ml of a dermatitis clear tincture and 100-150ml of 0.9% normal saline. The medical liquor disclosed by the invention has relatively strong effects of resisting inflammation, cleaning cutin and clearing away heat and toxic materials. Gentamicin and normal saline have a remarkable micrococcus epidermidis resisting effect and are used together, so that inflammation and papule of epidermis are quickly vanished, sewage is stopped, pruritus is relieved and relapse is reduced. The medical liquor disclosed by the invention is simple in formula, is externally coated at the affected parts, and is convenient to use and unique in effect. The medical liquor which is externally applied 1-2 times has a curative effect, and fast relieves itching, is high in cure rate and treats both symptoms and root causes.
Emactuzumab and RO7009789 will be administered intravenously (IV) at a starting dose of 500 milligrams (mg) for emactuzumab and 2 mg for RO7009789. Treatment will continue as long as there is clinical benefit until unacceptable toxicity, symptomatic deterioration, or withdrawal of consent.
Receive implantable loop recorder (ILR, Medtronic Reveal LINQ(TM)) with continuous monitoring, and will be followed by daily automated remote transmissions. Study visits are scheduled annually until the 4th visit, and furthermore, endpoints are collected via lookup in medical records and registries on at least an annual basis until the finalization of the trial.
Osteoporosis and osteoporotic vertebral fracture (OVF)s are the common diseases that affect the qualities of senior people. The general treatments for OVFs including percutaneous vertebroplasty (PVP) operation and conservative treatments with pain killers. But with the widely used methods, the life quality of patients were still not satisfied. Teriparatide has been proven to increase bone qualities in patients with severe osteoporosis and reduced the fracture possibilities. The investigators' previous clinical observation found teriparatide could be applied to treat fresh OVFs.

90 participants who diagnosed fresh OVFS were included in the trial. After they received each of three kinds of interventions mentioned in this study, The investigators followed up all these cases. Once 30 cases goal reaches in a certain group, the data collection in that special will stop automatically. The quality of life, pain score and BMDs will be evaluated in certain time during the trial.